<DOC>
	<DOC>NCT01458119</DOC>
	<brief_summary>This is a long term, open label study of migalastat HCl (AT1001) in subjects with Fabry disease who completed treatment in a previous monotherapy trial with migalastat hydrochloride (HCl).</brief_summary>
	<brief_title>Open-Label Phase 3 Long-Term Safety Study of Migalastat</brief_title>
	<detailed_description>AT1001-041 is an open-label, non-comparative, multicenter, long term extension study for subjects with Fabry disease who have completed treatment in a previous trial of migalastat HCl (also known as AT1001) given as monotherapy. This is an extension study designed to evaluate the long-term safety and efficacy of migalastat HCl for the treatment of Fabry disease. Study visits will occur every 6 months to evaluate safety and assess efficacy. Visit evaluations will include physical examination, clinical laboratory parameters, adverse events and patient reported outcomes.</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Completed migalastat HCl treatment in a previous Fabry disease protocol Both: both female and male participants are being studied Ages 16 years or older Males and females must agree to use protocol identified acceptable contraception Estimated glomerular filtration rate in the previous study was &lt;30 mL/min/1.73m2; unless there is measured GFR available within 3 months of Baseline Visit (Visit 1), which is &gt;30 mL/min/1.73m2 Has undergone, or is scheduled to undergo kidney transplantation or is currently on dialysis Pregnancy or breast feeding Treated with another investigational drug (except migalastat HCl) within 30 days of study start Unable to comply with study requirements, or deemed otherwise unsuitable for study entry, in the opinion of the investigator Has documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within the 12 months before Visit 1 Has clinically significant unstable cardiac disease in the opinion of the investigator Has history of allergy or sensitivity to AT1001 (including excipients) or other iminosugars Requires treatment with Glyset, (miglitol), or Zavesca (miglustat) Has any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements Patients with severe or unsuitable concomitant medical condition Patients with clinically significant abnormal laboratory value(s) and clinically significant electrocardiogram (ECG) findings at baseline.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>Lysosomal storage disease</keyword>
	<keyword>migalastat HCl</keyword>
	<keyword>AT1001</keyword>
</DOC>